#United States #San Diego #Lung Cancer #Genprex #Reqorsa

Genprex Highlights Breakthrough Preclinical Research at AACR 2026

In an exciting development for cancer therapy, Genprex, Inc. has unveiled promising preclinical results regarding its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), during the 2026 American Association for Cancer Research (AACR) Annual Meeting, which took place from April 17 to 22 in San Diego, California.

The presentation, made by Genprex’s esteemed research collaborators, was pivotal as it revealed the potential for Reqorsa® to become a game-changer in treating non-small cell lung cancer (NSCLC). Ryan Confer, the CEO of Genprex, emphasized the significance of identifying the TROP2 and PTEN biomarkers, which may predict a patient's response to Reqorsa®, thereby improving the strategies for patient selection in clinical trials. This aligns with Genprex’s goal of advancing precision medicine in lung cancer treatment.

Among the key findings presented, Reqorsa® was shown to induce apoptosis and significantly decrease tumor volumes in ALK-EML4-positive non-small cell lung cancer cell lines along with in vivo mouse models. The results were especially noteworthy as they demonstrated efficacy in tumors that had previously become resistant to current ALK inhibitors, such as alectinib. These findings highlight Reqorsa®’s dual potential — both as a standalone treatment and as a complementary therapy aimed at re-sensitizing resistant tumors.

Exploring Biomarkers: TROP2 and PTEN

One of the standout studies discussed at the AACR conference was centered on the role of TROP2 and PTEN as biomarkers for primary resistance to Reqorsa® gene therapy. Researchers established models resistant to TUSC2 gene therapy in NSCLC cell lines and patient-derived xenografts, revealing that 50% of the tested cell lines showed resistance. The identification of low TROP2 and high PTEN levels provided crucial insights, paving the way for refined therapeutic strategies that may enhance overall treatment efficacy in lung cancer patients.

Efficacy of Quaratusugene Ozeplasmid in Combo Treatments

In another compelling presentation, researchers evaluated how the quaratusugene ozeplasmid could effectively upregulate TUSC2 in EML4-ALK positive lung cancer models. The data supported the potential of combining Quar Oze with alectinib, resulting in impressive tumor shrinkage rates. In sensitive models, tumors reported a 79% shrinkage when treated with the combination compared to the standard therapy alone. This signifies a noteworthy advancement in treating advanced lung cancer, particularly cases where patients show resistance to conventional therapies.

Enhancing Immune Response Against Tumors

Moreover, another study has highlighted TUSC2's role in enhancing the activity of Natural Killer (NK) cells, essential for antitumor immunity. The experiments illustrated how restoring TUSC2 function could significantly boost NK cell cytotoxicity. Mice treated with Reqorsa® demonstrated successful tumor regression and an enhanced immune response, signaling TUSC2’s potential as a powerful immunomodulatory agent.

Looking Ahead: Towards Clinical Trials

Genprex is moving forward with optimism, as these preclinical results call for advancing towards clinical trials, focusing on optimizing treatments based on biomarker assessments. With the exhilarating data presented at AACR 2026, the roadmap looks promising for Genprex in their quest to develop innovative gene therapies for conditions currently lacking effective treatment options.

To wrap up, Genprex's presentation of preclinical findings at the AACR 2026 Annual Meeting showcases not just the potential of Reqorsa® gene therapy but also stands as a testament to the critical need for continued research in improving outcomes for lung cancer patients. The focus on personalized medicine and understanding tumor biology marks a significant shift in how oncologists may approach treatment strategies in the near future.